FDA Expands Approval for argenx's VYVGART to Cover All Adult gMG Patient Serotypes

Key Facts

argenx SE has announced that the U.S. FDA approved a label expansion for its treatments, VYVGART and VYVGART Hytrulo. The approval now covers all adult patient serotypes with generalized myasthenia gravis (gMG), including those who are triple seronegative. This regulatory milestone follows positive clinical data from the ADAPT SERON study, which demonstrated significant symptom improvement across diverse patient groups. By addressing previously unmet medical needs, this expansion significantly increases the addressable market for argenx's flagship products. Analysts view this development as a major bullish catalyst for the company's growth trajectory in the biotechnology sector. The decision underscores the clinical efficacy of the treatment and strengthens argenx's competitive position in the healthcare market.